LOS ANGELES--(BUSINESS WIRE)--
Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Endologix Inc. (“Endologix” or the “Company”) (ELGX) concerning possible violations of federal securities laws. Investors who purchased or otherwise acquired Endologix shares between August 2, 2016 and November 16, 2016 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the March 6, 2017 lead plaintiff motion deadline.
If you purchased or otherwise acquired Endologix shares and would like more information regarding the investigation, we encourage you to click here, or contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at firstname.lastname@example.org.
Endologix designs, manufactures and sells medical products intended to treat abdominal aortic aneurysms.
Nellix is used as Endologix’s endovascular aneurysm sealing system for infrarenal abdominal aortic aneurysms. Endologix stated that it would approve the initial version of the Nellix system used in the Nellix investigational device exemption (IDE) clinical trial, the EVAS FORWARD-IDE Study.
On November 16, 2016 however, Endologix revealed that the FDA requested a two-year follow-up on patients in the EVAS-FORWARD-IDE study to accurately measure Nellix.
On December 27, 2016 Endologix revealed that it was temporarily holding AFX Endovascular AAA System shipments, due to an investigation of a manufacturing problem.
When this information was released to the public, the value of Endologix fell 20%, causing investors harm.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at email@example.com.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.